UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 613, 2026

iSpecimen Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40501		27-0480143
(State or other jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

8 Cabot Road, Suite 1800
Woburn, MA 01801

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (781) 301-6700

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ISPC		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 78.01. ~~Regulation~~Other ~~FD Disclosure~~Events.

On ~~February~~December 631, ~~2026~~2025, iSpecimen Inc. (the “Company”) ~~issued~~convened ~~two~~its ~~press~~2025 ~~releases~~Annual Meeting of Stockholders (the “Annual Meeting”). Because a quorum was not present, the Company adjourned the Annual Meeting to permit additional time for stockholders to vote on the proposals set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 21, 2025 (the “Proxy Statement”).

The ~~first~~Annual ~~press~~Meeting ~~release~~was ~~announced~~reconvened ~~the~~on ~~successful~~January ~~completion of Milestone~~23, 22026 ~~in the Company’s digital transformation program powered by SalesStack Solutions~~ and ~~the~~again ~~activation~~on ofFebruary ~~the~~13, ~~Company’s live production marketplace~~2026. AAt ~~copy~~each ofreconvened ~~this~~meeting, ~~press~~a ~~release~~quorum iswas ~~furnished~~not aspresent ~~Exhibit~~and ~~99.1~~the toAnnual ~~this~~Meeting ~~Current~~was ~~Report on Form 8-K~~adjourned.

The ~~second~~Company ~~press~~intends ~~release~~to ~~highlights~~reconvene ~~recent~~the ~~operational~~Annual ~~achievements~~Meeting ~~demonstrating~~on ~~the~~March ~~strength~~13, ~~and~~2026, ~~responsiveness~~at of9:00 ~~the~~a.m. ~~Company’s~~Eastern ~~site~~Time. ~~network~~The inrecord ~~supporting~~date ~~customer~~for ~~research,~~determination ~~including~~of ~~rapid~~stockholders ~~influenza specimen~~entitled ~~procurement.~~to Avote ~~copy~~at ofthe ~~this~~Annual ~~press~~Meeting remains ~~release~~November is3, ~~furnished~~2025. asNo ~~Exhibit~~changes ~~99.2~~have been made to ~~this~~the ~~Current~~proposals ~~Report~~to be voted on ~~Form~~at ~~8-K~~the Annual Meeting, which are described in the Proxy Statement.

~~The information in this Item 7.01 and Exhibit 99.~~1 and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

~~Item 9.01. Financial Statements and Exhibits.~~SIGNATURE

~~(d)~~Pursuant ~~Exhibits~~to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit No.		Description
99.1		Press Release dated February 6, 2026 (Milestone 2 Announcement)
99.2		Press Release dated February 6, 2026 (Operational Achievements Announcement)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Dated: February 18, 2026

1iSPECIMEN INC. By: /s/ Katharyn Field Name: Katharyn Field Title: Chief Executive Officer

~~SIGNATURE~~2

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 6, 2026

iSPECIMEN INC. By: /s/ Katharyn Field Name: Katharyn Field Title: Chief Executive Officer

Filing Compare · iSpecimen Inc.